1. |
国家药品监督管理局药品审评中心. 真实世界证据支持药物研发与审评的指导原则(试行), 2020. Available at: https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200107151901190.html.
|
2. |
国家药品监督管理局. 真实世界数据用于医疗器械临床评价技术指导原则(试行), 2020. Available at: https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20201126090030150.html.
|
3. |
Zelen M. A new design for randomized clinical trials. N Engl J Med, 1979, 300(22): 1242-1245.
|
4. |
Kim SY, Flory J, Relton C. Ethics and practice of trials within cohorts: an emerging pragmatic trial design. Clin Trials, 2018, 15(1): 9-16.
|
5. |
Simon GE, Shortreed SM, DeBar LL. Zelen design clinical trials: why, when, and how. Trials, 2021, 22(1): 541.
|
6. |
周奋, 詹绍康. 随机化临床试验新的设计方案探讨. 数理医药学杂志, 1993, (3): 36-38.
|
7. |
Kalkman S, van Thiel GJMW, Zuidgeest MGP, et al. Series: Pragmatic trials and real world evidence: Paper 4. Informed consent. J Clin Epidemiol, 2017, 89: 181-187.
|
8. |
Horwitz RI, Feinstein AR. Advantages and drawbacks of the zelen design for randomized clinical trials. J Clin Pharmacol, 1980, 20(7): 425-427.
|
9. |
Velthuis MJ, May AM, Monninkhof EM, et al. Alternatives for randomization in lifestyle intervention studies in cancer patients were not better than conventional randomization. J Clin Epidemiol, 2012, 65(3): 288-292.
|
10. |
Touzet S, Occelli P, Schröder C, et al. Impact of the early start denver model on the cognitive level of children with autism spectrum disorder: study protocol for a randomised controlled trial using a two-stage Zelen design. BMJ Open, 2017, 7(3): e014730.
|
11. |
Faden R, Kass N, Whicher D, et al. Ethics and informed consent for comparative effectiveness research with prospective electronic clinical data. Med Care, 2013, 51(Suppl 3): S53-S57.
|
12. |
McHugh R. Validity and treatment dilution in Zelen's single consent design. Stat Med, 1984, 3(3): 215-218.
|
13. |
Zelen M. Randomized consent designs for clinical trials: an update. Stat Med, 1990, 9(6): 645-656.
|
14. |
Anbar D. The relative efficiency of zelen's prerandomization design for clinical trials. Biometrics, 1983, 39(3): 711-718.
|
15. |
Altman DG, Whitehead J, Parmar MK, et al. Randomised consent designs in cancer clinical trials. Eur J Cancer, 1995, 31A(12): 1934-1944.
|
16. |
Haynes B. Can it work. Does it work? Is it worth it? The testing of healthcareinterventions is evolving. BMJ, 1999, 319(7211): 652-653.
|
17. |
Homer CS. Using the Zelen design in randomized controlled trials: debates and controversies. J Adv Nurs, 2002, 38(2): 200-207.
|
18. |
Campbell R, Peters T, Grant C, et al. Adapting the randomized consent (Zelen) design for trials of behavioural interventions for chronic disease: feasibility study. J Health Serv Res Policy, 2005, 10(4): 220-225.
|
19. |
Land J, McCourt O, Heinrich M, et al. The adapted Zelen was a feasible design to trial exercise in myeloma survivors. J Clin Epidemiol, 2020, 125: 76-83.
|
20. |
王雯, 谭婧, 任燕, 等. 重新认识真实世界数据研究: 更新与展望. 中国循证医学杂志, 2020, 20(11): 1241-1246.
|
21. |
Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ, 2018, 363: k3532.
|
22. |
Torgerson DJ, Roland M. What is Zelen's design. BMJ, 1998, 316(7131): 606.
|
23. |
Koutoukidis DA, Land J, Hackshaw A, et al. Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design. Br J Cancer, 2020, 123(2): 187-195.
|
24. |
Faseru B, Ellerbeck EF, Catley D, et al. Changing the default for tobacco-cessation treatment in an inpatient setting: study protocol of a randomized controlled trial. Trials, 2017, 18(1): 379.
|